GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.
Considerable on MSN
GSK buys Rapt in $2.2B deal
GSK agreed to acquire Rapt Therapeutics for $2.2 billion on Tuesday, a move that ...
GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...
Zacks Investment Research on MSN
GSK to boost respiratory & immunology pipeline with $2.2B RAPT buyout
GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics ...
GSK has agreed to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing novel ...
GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...
South Korean biotech Alteogen (Kosdaq: 196170) has signed an exclusive license agreement with Tesaro, a unit of GSK (LSE: GSK ...
GSK to acquire California-based biopharma company, RAPT Therapeutics for $2.2 billion: London, UK Tuesday, January 20, 2026, 16:45 Hrs [IST] GSK plc announced that it has entered ...
GSK and Flagship Pioneering announced a collaboration on Monday morning to discover and develop a portfolio of medicines and vaccines, with a focus on respiratory and immunology therapeutic areas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results